Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6730282 | 0.80 | ALDH1A1 (0.38) | KDM4CALDH1A1CYP2D6CYP2C19EPHX1 | |
| SCHEMBL2214465 | 0.78 | LMNA (0.41) | KDM4CALDH1A1CYP2D6CYP2C19EPHX1 | |
| SCHEMBL2214528 | 0.72 | LMNA (0.36) | KDM4CALDH1A1CYP2D6CYP2C19LMNA | |
| SCHEMBL10426442 | 0.71 | ALDH1A1 (0.35) | KDM4CALDH1A1EPHX1 | |
| SCHEMBL1934610 | 0.69 | — | — | |
| SCHEMBL6729276 | 0.69 | SMN1; SMN2 (0.38) | KDM4CALDH1A1CYP2D6CYP2C19EPHX1 | |
| SCHEMBL631310 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL11159957 | 0.67 | CYP2D6 (0.40) | KDM4CALDH1A1CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL27915791 | 0.67 | — | — | |
| SCHEMBL5273019 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186170-A1 | Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient | EGIS GYOGYSZERGYAR (HU) | 2004-09-23 | — | — | US | disclosed |
| EP-0500136-B1 | 1,2,4-Triazolo[1,5-a]pyrimidine derivatives, a process for preparing them as well as medicaments containing them and the use of them | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1996-05-15 | — | — | EP | disclosed |
| EP-0500136-A1 | 1,2,4-Triazolo[1,5-a]pyrimidine derivatives, a process for preparing them as well as medicaments containing them and the use of them | EGIS GYOGYSZERGYAR (HU) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186170-A1 | Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient | CYP2F1, CYP3A4, CYP2S1 | KDM4C 1281/4885ALDH1A1 81/4885CYP2D6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.